title: A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
abstract: OBJECTIVE
  To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR).
  
  
  METHODS
  35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally.
  
  
  RESULTS
  One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS.
  
  
  CONCLUSIONS
  Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.
authors.affiliation: Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: M
authors.initials: M
authors.lastname: Juretzka
authors.forename: M L
authors.initials: ML
authors.lastname: Hensley
authors.forename: W
authors.initials: W
authors.lastname: Tew
authors.forename: J
authors.initials: J
authors.lastname: Konner
authors.forename: C
authors.initials: C
authors.lastname: Aghajanian
authors.forename: M
authors.initials: M
authors.lastname: Leitao
authors.forename: A
authors.initials: A
authors.lastname: Iasonos
authors.forename: R
authors.initials: R
authors.lastname: Soslow
authors.forename: K
authors.initials: K
authors.lastname: Park
authors.forename: P
authors.initials: P
authors.lastname: Sabbatini
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001549:Benzamides; D018572:Disease-Free Survival; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate